Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1644 1646 1674
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18216026 | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer | Non-Final OA | Janssen Biotech, Inc. |
| 18300683 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone | Final Rejection | Janssen Biotech, Inc. |
| 18300288 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone | Non-Final OA | Janssen Biotech, Inc. |
| 18522074 | Systems And Methods For Genetic Analysis Of Metastases | Non-Final OA | Nantomics LLC |
| 18020515 | PLASMA EXCHANGE REMOVAL OF SPD-L1 | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17769171 | COMPOSITIONS AND METHODS FOR DETECTING PLXDC1 AND PLXDC2 IN HUMAN TISSUES | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17286083 | Methods to Diagnose and Treat Cancer Using Non-Human Nucleic Acids | Final Rejection | The Regents of the University of California |
| 18264799 | METHODS OF TREATING CANCER BY ADMINISTERING A NEOADJUVANT PD-1 INHIBITOR | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18038321 | USE OF INSULIN-LIKE GROWTH FACTORS WITH GAMMA-CHAIN CYTOKINES TO INDUCE HOMEOSTATIC PROLIFERATION OF LYMPHOCYTES | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 17616246 | BREAST CANCER DETECTION METHODS | Non-Final OA | Cambridge Enterprise Limited |
| 18035399 | VISTA AGONIST FOR TREATMENT/PREVENTION OF ISCHEMIC AND/OR REPERFUSION INJURY | Non-Final OA | THE TRUSTEES OF DARTMOUTH COLLEGE |
| 18311991 | METHODS FOR TREATING OR PREVENTING HEADACHE DISORDERS | Final Rejection | WASHINGTON UNIVERSITY |
| 18249830 | CIRCULATING MICROVESICLES EXPRESSING CARBONIC ANHYDRASE 9 FOR THE PROGNOSIS OF RENAL CELL CARCINOMA | Final Rejection | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
| 17801547 | INHIBITION OF FKBP1A FOR THE TREATMENT OF TRIPLE-NEGATIVE MAMMARY CARCINOMA | Non-Final OA | Heinrich-Heine-Universität Düsseldorf |
| 18179699 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS, COMBINATIONS AND METHODS OF USE | Non-Final OA | Mersana Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy